Is Alpine Immune Sciences (ALPN) a Sell? What does Wedbush Think?

May 18, 2018 - By John Moody

Why Has Wedbush Given Alpine Immune Sciences (ALPN) a $13 Price Target

In a research note published today, Wedbush analysts has initiated Alpine Immune Sciences (ALPN) coverage with Outperform rating, and a $13 price target.

The stock increased 8.50% or $0.69 during the last trading session, reaching $8.81. About 26,798 shares traded or 23.52% up from the average. Alpine Immune Sciences, Inc. (ALPN) has declined 32.63% since May 18, 2017 and is downtrending. It has underperformed by 44.18% the S&P500.

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. The company has market cap of $121.98 million. The Company’s lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. It currently has negative earnings. The firm has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein immunotherapies targeting the immune synapse to treat cancer.

More recent Alpine Immune Sciences, Inc. (NASDAQ:ALPN) news were published by: Seekingalpha.com which released: “Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant” on May 11, 2018. Also Businesswire.com published the news titled: “Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors” on April 24, 2018. Businesswire.com‘s news article titled: “Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results” with publication date: May 14, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: